Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $571.17M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.23M
Average 0.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -32.1% | +323.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -32.1% over three years. Forward estimates point to Revenue at +323.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Opus Genetics, Inc. NASDAQ:IRD | $331.12M | $3.98 | Not rated | -33.0 | +111.40% |
Agenus Inc. NASDAQ:AGEN | $304.51M | $6.73 | Not rated | 1.7 | +43.12% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -1.16% |
Anixa Biosciences, Inc. NASDAQ:ANIX | $91.08M | $2.62 | Not rated | -9.3 | -40.91% |
TuHURA Biosciences, Inc. NASDAQ:HURA | $88.58M | $1.39 | Not rated | -4.6 | -14.47% |
Seer, Inc. NASDAQ:SEER | $87.63M | $1.57 | Not rated | -1.4 | -28.61% |
Spero Therapeutics, Inc. NASDAQ:SPRO | $58.23M | $1.00 | Undervalued | 8.2 | -61.33% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $15.48M | $0.21 | Not rated | -1.3 | +46.79% |
Seres Therapeutics, Inc. NASDAQ:MCRB | $14.27M | $1.40 | Overvalued | -1.3 | -75.67% |
Continue the stock analysis
Jump to another research area for this company.